Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma. - Wikidata - wikimedia - TriplyDB

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

http://www.wikidata.org/entity/Q37107396

about

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

http://www.wikidata.org/entity/Q37107396

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@en

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@nl

type

label

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@en

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@nl

prefLabel

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@en

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@nl

P1433

Q37107396-157786F2-8826-4BDC-8CA1-D05D79BBE0E8

P1476

Q37107396-20A14F5D-7687-4381-9E93-EC45F90BD28B

P2093

Q37107396-1EB9A707-095B-4BA3-AF1F-C5C89939431C

Q37107396-3DEB47C9-CF16-4D0D-BD9A-8D8694F368D7

Q37107396-68F9FD9D-F655-4B5D-B873-DB7DC001937B

Q37107396-6CC0E5AF-91EE-4F6E-B4E6-7F36D714AB41

Q37107396-9985641E-22BA-43FB-B1CC-EDC35642E3CF

Q37107396-A010D332-F1F4-473E-8A5A-394D7679C130

Q37107396-A3F9DFC9-094A-4F51-8358-B56FA0BE68E5

Q37107396-C12C9C1A-40B5-46B6-877F-78BF3CD77C8F

Q37107396-FB3D9002-8672-4C22-A9F6-FE758537FABC

P2860

Q37107396-0B3E9732-5439-4DF1-B7DC-17315BAEDFBA

Q37107396-1281D64D-97A7-4448-B535-534C49EDF325

Q37107396-3E2B969C-825E-4134-8F6B-9642B2F6A176

Q37107396-501D3F71-2F2F-4C0D-A1AE-8410D6C09D06

Q37107396-5C326927-D4DD-4424-B4CE-F1D1B1C29F69

Q37107396-64F536FC-C550-41EE-A8E5-9107807B3181

Q37107396-7110C4DA-326B-42AC-AF0E-052C00DDED5E

Q37107396-9F08462F-CC89-4C36-84E1-F06C1AA6C8BB

Q37107396-ACF3226E-5D43-431D-8997-663CBF2CC5EE

Q37107396-BA2A7501-97A4-4FE3-8532-7645374DA619

P304

Q37107396-AC92A937-8A33-4F76-86F1-C527AB29A42B

P31

Q37107396-720D6964-A9D0-4849-BFFE-9C1B3FCA53BA

P356

Q37107396-1603ED05-B16B-48A1-AF6D-2473C79BEA8A

P433

Q37107396-8EE475B0-230E-4D07-91EC-F29AEDF9DC85

P478

Q37107396-C4F25BC6-74DD-4CC4-9FCA-A8C13126BC7C

P577

Q37107396-50D13C34-C235-464B-9786-D47DFDB23D1E

P698

Q37107396-C476A37D-7DE6-4A7F-9B0B-9EECC2A1CDE4

P932

Q37107396-7AE84F40-D01D-44DA-BC52-A825C41FA378

P356

P1433

Oncology Letters

P1476

Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.

@en

P2093

Chuyu Jing

http://www.w3.org/2001/XMLSchema#string

Junfei Chen

http://www.w3.org/2001/XMLSchema#string

Liyu Jiang

http://www.w3.org/2001/XMLSchema#string

Qiang Huo

http://www.w3.org/2001/XMLSchema#string

Qifeng Yang

http://www.w3.org/2001/XMLSchema#string

Tingting Ma

http://www.w3.org/2001/XMLSchema#string

Xiaoli Kong

http://www.w3.org/2001/XMLSchema#string

Xiaoting Wang

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Li

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Current status of diagnosis and treatment of primary breast cancer in beijing, 2008.

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

Weekly paclitaxel in the adjuvant treatment of breast cancer.

Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China.

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

P304

1448-1454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2016.4754

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27446451

http://www.w3.org/2001/XMLSchema#string

P932

4950445

http://www.w3.org/2001/XMLSchema#string